HRP20170366T1 - Proizvodnja aktivnih visoko fosforiliranih ljudskih enzima lizosomske sulfataze i njihova uporaba - Google Patents
Proizvodnja aktivnih visoko fosforiliranih ljudskih enzima lizosomske sulfataze i njihova uporaba Download PDFInfo
- Publication number
- HRP20170366T1 HRP20170366T1 HRP20170366TT HRP20170366T HRP20170366T1 HR P20170366 T1 HRP20170366 T1 HR P20170366T1 HR P20170366T T HRP20170366T T HR P20170366TT HR P20170366 T HRP20170366 T HR P20170366T HR P20170366 T1 HRP20170366 T1 HR P20170366T1
- Authority
- HR
- Croatia
- Prior art keywords
- galns
- enzyme
- galns enzyme
- preparation
- use according
- Prior art date
Links
- 230000002132 lysosomal effect Effects 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 102000005262 Sulfatase Human genes 0.000 title 1
- 108060007951 sulfatase Proteins 0.000 title 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 claims 23
- 101001066305 Homo sapiens N-acetylgalactosamine-6-sulfatase Proteins 0.000 claims 20
- 238000002360 preparation method Methods 0.000 claims 12
- 208000025797 Mucopolysaccharidosis type 4A Diseases 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims 4
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 claims 4
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 claims 3
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 claims 3
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 claims 3
- 238000010186 staining Methods 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 238000011537 Coomassie blue staining Methods 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 101710099863 N-acetylgalactosamine-6-sulfatase Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000049489 human GALNS Human genes 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06001—Arylsulfatase (3.1.6.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
Claims (11)
1. Pripravak rekombinantnog ljudskog enzima N-acetilgalaktozamin-6-sulfataze (GALNS), navedeni pripravak enzima sadrži GALNS enzime koji obuhvaćaju sekvencu amino kiseline koja je barem 95% identična s amino kiselinama 27 do 522 iz SEQ ID NO:4, koji je koristan za liječenje lizosomske bolesti nakupljanja koja je uzrokovana s ili povezana s nedostatkom u navedenom GALNS, pri čemu navedeni GALNS enzimi u navedenom pripravku:
(a) imaju barem 50% konverziju cisteinskog ostatka na položaju 53 u Ca-formilglicin (FGly); i
(b) su N-povezano glikozilirani na asparaginskim ostatcima na položajima 178 i 397, te pri čemu je barem 50% oligomanoznih lanaca vezanih na asparaginski ostatak na položaju 178 bis-fosforiliranih,
proizvoljno pri čemu GALNS enzim je fuzijski protein koji sadrži signal staničnog ciljanja smješten na N- ili C-terminalnom kraju GALNS enzima.
2. Pripravak GALNS enzima prema zahtjevu 1, naznačen time da lizosomska bolest nakupljanja je mukopolisaharidoza tip IVa (MPS IVa) ili Morquio A sindrom, ili višestruki nedostatak sulfataza.
3. Pripravak GALNS enzima prema bilo kojem od zahtjeva 1 ili 2, naznačen time da se GALNS enzim sastoji od glavnog pojasa od 55-60 kDa koji je barem 75% od vidljivih proteina, ili barem 85% od vidljivih proteina, kako je određeno bojenjem s Coomassie Blue kada je podvrgnut SDS-PAGE pod uvjetima redukcije.
4. Pripravak GALNS enzima prema bilo kojem od zahtjeva 1 ili 2, naznačen time da se GALNS enzim sastoji od glavnog pojasa od 55-60 kDa koji je barem oko 90% od vidljivih proteina kako je određeno bojenjem s Coomassie Blue kada je podvrgnut SDS-PAGE pod uvjetima redukcije.
5. Pripravak GALNS enzima prema bilo kojem od zahtjeva 1 do 4, naznačen time da GALNS enzim ima barem 70% konverziju cisteinskog ostatka na položaju 53 u Ca-formilglicin (FGly).
6. Pripravak GALNS enzima prema bilo kojem od zahtjeva 1 do 4, naznačen time da GALNS enzim ima barem 90% konverziju cisteinskog ostatka na položaju 53 u Ca-formilglicin (FGly).
7. Pripravak prema zahtjevu 1 naznačen time da je za uporabu za liječenje mukopolisaharidoze tip IVa (MPS IVa) ili Morquio A sindroma, ili višestrukog nedostatka sulfataza (MSD).
8. Uporaba pročišćenog, rekombinantnog ljudskog enzima N-acetilgalaktozamin-6-sulfataze (GALNS) pripravka prema bilo kojem od zahtjeva 1 do 6 naznačena time da je za proizvodnju lijeka za liječenje mukopolisaharidoze tip IVa (MPS IVa) ili Morquio A sindroma, ili višestrukog nedostatka sulfataza (MSD).
9. Pripravak za uporabu prema zahtjevu 7 ili uporaba prema zahtjevu 8, naznačen time da se GALNS enzim sastoji od glavnog pojasa od 55-60 kDa koji je barem 75% od vidljivih proteina, ili barem 85% od vidljivih proteina, kako je određeno bojenjem s Coomassie Blue kada je podvrgnut SDS-PAGE pod uvjetima redukcije.
10. Pripravak za uporabu prema zahtjevu 7 ili uporaba prema zahtjevu 8, naznačen time da se GALNS enzim sastoji od glavnog pojasa od 55-60 kDa koji je barem 90% od vidljivih proteina kako je određeno bojenjem s Coomassie Blue kada je podvrgnut SDS-PAGE pod uvjetima redukcije.
11. Pripravak za uporabu prema bilo kojem od zahtjeva 7 do 10 ili uporaba prema bilo kojem od zahtjeva 8 do 10, naznačen time da GALNS enzim ima barem 70% konverziju cisteinskog ostatka na položaju 53 u Ca-formilglicin (FGly).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2217908P | 2008-01-18 | 2008-01-18 | |
| US9937308P | 2008-09-23 | 2008-09-23 | |
| US11024608P | 2008-10-31 | 2008-10-31 | |
| EP09702074.7A EP2245145B1 (en) | 2008-01-18 | 2009-01-16 | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| PCT/US2009/031276 WO2009091994A2 (en) | 2008-01-18 | 2009-01-16 | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170366T1 true HRP20170366T1 (hr) | 2017-05-05 |
Family
ID=40451345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170366TT HRP20170366T1 (hr) | 2008-01-18 | 2017-03-06 | Proizvodnja aktivnih visoko fosforiliranih ljudskih enzima lizosomske sulfataze i njihova uporaba |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8128925B2 (hr) |
| EP (2) | EP3219795B1 (hr) |
| JP (1) | JP5687069B2 (hr) |
| KR (1) | KR101744142B1 (hr) |
| CN (2) | CN102027110A (hr) |
| AR (1) | AR070198A1 (hr) |
| AU (1) | AU2009205978B2 (hr) |
| BR (1) | BRPI0906948B1 (hr) |
| CA (2) | CA3112632A1 (hr) |
| CL (1) | CL2009000091A1 (hr) |
| CY (2) | CY1118984T1 (hr) |
| DK (1) | DK2245145T3 (hr) |
| HK (1) | HK1244505A1 (hr) |
| HR (1) | HRP20170366T1 (hr) |
| HU (2) | HUE032074T2 (hr) |
| IL (1) | IL206975A (hr) |
| LT (2) | LT2245145T (hr) |
| MX (1) | MX2010007846A (hr) |
| NL (1) | NL300874I2 (hr) |
| NO (1) | NO2017024I1 (hr) |
| PE (2) | PE20140841A1 (hr) |
| PL (1) | PL2245145T3 (hr) |
| PT (1) | PT2245145T (hr) |
| RU (1) | RU2510820C2 (hr) |
| SI (1) | SI2245145T1 (hr) |
| TW (1) | TWI395816B (hr) |
| WO (1) | WO2009091994A2 (hr) |
| ZA (1) | ZA201004674B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101811057B1 (ko) | 2007-04-03 | 2017-12-20 | 옥시레인 유케이 리미티드 | 분자의 글리코실화 |
| CA3112632A1 (en) | 2008-01-18 | 2009-07-23 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| BR112012007099A2 (pt) | 2009-09-29 | 2015-09-15 | Oxyrane Uk Ltd | hidrólise da ligação manose-1-fosfo-6-manose a fosfo-manose |
| KR20130055555A (ko) | 2009-11-19 | 2013-05-28 | 옥시레인 유케이 리미티드 | 효모 스트레인 생성용 포유류 유사 복합 ｎ-글리칸들 |
| AR082319A1 (es) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| CA2812870C (en) | 2010-09-29 | 2020-06-09 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| CA2812872C (en) | 2010-09-29 | 2021-08-03 | Oxyrane Uk Limited | De-mannosylation of phosphorylated n-glycans |
| US20130236442A1 (en) * | 2010-11-12 | 2013-09-12 | Green Cross Corporation | Iduronate-2-sulfatase and use thereof |
| ES2661967T3 (es) * | 2010-12-22 | 2018-04-04 | Fondazione Telethon | Estrategias terapéuticas para tratar patologías del SNC en mucopolisacaridosis |
| TW201307563A (zh) * | 2011-05-19 | 2013-02-16 | Shire Human Genetic Therapies | 純化乙醯肝素－ｎ－硫酸酯酶之方法 |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| AU2013234042B2 (en) | 2012-03-15 | 2017-11-02 | Oxyrane Uk Limited | Methods and materials for treatment of Pompe's disease |
| WO2013148323A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies | Methods of analyzing and preparing protein compositions |
| US20140004097A1 (en) * | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (ko) * | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) * | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| NZ707753A (en) * | 2012-11-13 | 2019-07-26 | Chiesi Farm Spa | Purification of recombinant human galactocerebroside β-galactosidase (rhgalc) |
| WO2014136065A2 (en) * | 2013-03-05 | 2014-09-12 | Oxyrane Uk Limited | Production of catalytically active type i sulfatase |
| CN105980859B (zh) * | 2014-02-18 | 2018-10-19 | 夏尔人类遗传性治疗公司 | 针对溶酶体酶的底物清除测定 |
| RU2708026C2 (ru) * | 2014-04-01 | 2019-12-03 | Свидиш Орфан Биовитрум Аб (Пабл) | Модифицированная сульфамидаза и способ её получения |
| EP3101125A1 (en) * | 2015-06-05 | 2016-12-07 | Laboratorios Del Dr. Esteve, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
| AU2016349528A1 (en) | 2015-11-06 | 2018-05-17 | Biomarin Pharmaceutical Inc. | Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes |
| RU2673038C2 (ru) * | 2016-01-18 | 2018-11-21 | ООО "Международный Биотехнологический Центр "Генериум" | Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа |
| JP6430980B2 (ja) * | 2016-03-09 | 2018-11-28 | フォンダッツィオーネ・テレソン | ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略 |
| JP6957738B2 (ja) * | 2017-08-31 | 2021-11-02 | グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． | スルファターゼタンパク質を精製する方法 |
| KR20200058510A (ko) | 2017-10-02 | 2020-05-27 | 데날리 테라퓨틱스 인크. | 효소 대체 요법 효소를 포함하는 융합 단백질 |
| WO2020223215A1 (en) * | 2019-04-29 | 2020-11-05 | The University Of North Carolina At Chapel Hill | Optimized sumf1 genes and expression cassettes and their use |
| RU2763990C2 (ru) * | 2020-02-19 | 2022-01-12 | Акционерное общество "ГЕНЕРИУМ" | Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки |
| IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| AU2022329856A1 (en) * | 2021-08-18 | 2024-03-28 | Joint-Stock Company "Generium" | Targeted delivery of therapeutic enzymes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US7083793B2 (en) | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| US6972124B2 (en) | 2000-05-01 | 2005-12-06 | Biomarin Pharmaceuticals Inc. | Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| JP4307079B2 (ja) | 2001-01-26 | 2009-08-05 | セレキス エスアー | マトリックス付着領域およびその使用方法 |
| US20030040095A1 (en) * | 2001-03-16 | 2003-02-27 | Achille Arini | Method for the production of pharmaceutically active recombinant proteins |
| AUPS293002A0 (en) * | 2002-06-14 | 2002-07-04 | Women's And Children's Hospital | Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders |
| DK2325302T3 (en) | 2003-02-11 | 2016-03-14 | Shire Human Genetic Therapies | Cells expressing a sulfatase and a C-formylglycine-generating enzyme and methods and uses thereof |
| AU2005209360B2 (en) | 2004-01-30 | 2009-06-25 | Takeda Pharmaceutical Company Limited | Production and purification of recombinant arylsulfatase A |
| EP1720405A4 (en) * | 2004-02-06 | 2008-08-27 | Biomarin Pharm Inc | MANUFACTURE OF HIGHLY PHOSPHORYLATED LYSOSOMAL ENZYMES AND USES THEREOF |
| WO2005113765A2 (en) * | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
| US7863238B2 (en) | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
| CA2607133A1 (en) | 2005-05-02 | 2006-11-09 | Toray Industries, Inc. | Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer |
| EP1818395A1 (en) | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
| CA2674493C (en) * | 2007-01-05 | 2017-05-09 | Massachusetts Institute Of Technology | Compositions of and methods of using sulfatases from flavobacterium heparinum |
| WO2009034159A1 (en) | 2007-09-12 | 2009-03-19 | Vivendy Therapeutics Ltd: | Short polypeptide mediated conformational changes promoting enhancement of enzymatic activity |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| CA3112632A1 (en) | 2008-01-18 | 2009-07-23 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
-
2009
- 2009-01-16 CA CA3112632A patent/CA3112632A1/en active Pending
- 2009-01-16 LT LTEP09702074.7T patent/LT2245145T/lt unknown
- 2009-01-16 CN CN2009801088873A patent/CN102027110A/zh active Pending
- 2009-01-16 AR ARP090100152A patent/AR070198A1/es not_active Application Discontinuation
- 2009-01-16 CL CL2009000091A patent/CL2009000091A1/es unknown
- 2009-01-16 CN CN201510546716.6A patent/CN105274072A/zh active Pending
- 2009-01-16 RU RU2010134412/10A patent/RU2510820C2/ru active
- 2009-01-16 SI SI200931624A patent/SI2245145T1/sl unknown
- 2009-01-16 AU AU2009205978A patent/AU2009205978B2/en active Active
- 2009-01-16 EP EP16203748.5A patent/EP3219795B1/en active Active
- 2009-01-16 PE PE2014000125A patent/PE20140841A1/es active IP Right Grant
- 2009-01-16 PE PE2009000053A patent/PE20091319A1/es active IP Right Grant
- 2009-01-16 JP JP2010543278A patent/JP5687069B2/ja active Active
- 2009-01-16 CA CA2711590A patent/CA2711590C/en active Active
- 2009-01-16 KR KR1020107018344A patent/KR101744142B1/ko active IP Right Grant
- 2009-01-16 WO PCT/US2009/031276 patent/WO2009091994A2/en active Application Filing
- 2009-01-16 PL PL09702074T patent/PL2245145T3/pl unknown
- 2009-01-16 BR BRPI0906948-8A patent/BRPI0906948B1/pt active IP Right Grant
- 2009-01-16 EP EP09702074.7A patent/EP2245145B1/en active Active
- 2009-01-16 US US12/355,453 patent/US8128925B2/en active Active
- 2009-01-16 DK DK09702074.7T patent/DK2245145T3/en active
- 2009-01-16 HU HUE09702074A patent/HUE032074T2/en unknown
- 2009-01-16 PT PT97020747T patent/PT2245145T/pt unknown
- 2009-01-16 MX MX2010007846A patent/MX2010007846A/es active IP Right Grant
- 2009-01-17 TW TW098101816A patent/TWI395816B/zh active
-
2010
- 2010-07-02 ZA ZA2010/04674A patent/ZA201004674B/en unknown
- 2010-07-13 IL IL206975A patent/IL206975A/en active IP Right Grant
-
2012
- 2012-02-10 US US13/371,082 patent/US8420368B2/en active Active
-
2013
- 2013-03-21 US US13/848,561 patent/US9200264B2/en active Active
-
2015
- 2015-10-27 US US14/924,405 patent/US9873867B2/en active Active
-
2017
- 2017-03-06 HR HRP20170366TT patent/HRP20170366T1/hr unknown
- 2017-03-13 CY CY20171100313T patent/CY1118984T1/el unknown
- 2017-05-18 HU HUS1700022C patent/HUS1700022I1/hu unknown
- 2017-05-19 NL NL300874C patent/NL300874I2/nl unknown
- 2017-05-19 CY CY2017018C patent/CY2017018I2/el unknown
- 2017-05-25 LT LTPA2017016C patent/LTC2245145I2/lt unknown
- 2017-05-30 NO NO2017024C patent/NO2017024I1/no unknown
-
2018
- 2018-01-12 US US15/869,549 patent/US10563183B2/en active Active
- 2018-03-20 HK HK18103885.2A patent/HK1244505A1/zh unknown
-
2020
- 2020-02-06 US US16/783,589 patent/US10934534B2/en active Active
-
2021
- 2021-03-01 US US17/188,994 patent/US20210189357A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170366T1 (hr) | Proizvodnja aktivnih visoko fosforiliranih ljudskih enzima lizosomske sulfataze i njihova uporaba | |
| HRP20180291T1 (hr) | Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja | |
| HRP20200428T1 (hr) | Sastavi alfa-galaktozidaze | |
| ES2542350T3 (es) | Composición detergente para lavavajillas | |
| EP2455461A3 (en) | Lipase variants for pharmaceutical use | |
| WO2012125937A3 (en) | Glycosyl hydrolase enzymes and uses thereof for biomass hydrolysis | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| SG164386A1 (en) | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | |
| MX347545B (es) | Polipeptidos con actividad xilanasa. | |
| WO2010059424A3 (en) | Methods and compositions for degrading cellulosic material | |
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| RU2385928C3 (ru) | Продуцирование высокоманнозных белков в растительных культурах | |
| HRP20161320T4 (hr) | Kimerni polipeptidi i njihova upotreba u dekoloniziranju bakterija | |
| WO2013006486A3 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| RS53505B1 (en) | OXYTOMODULIN PEPTIDE ANALOG | |
| MXPA06001173A (es) | Metodo analitico para la pancreatina y composiciones comparables. | |
| IL189193A (en) | Transplastic plants expressing a space-oriented protein | |
| Juge et al. | The activity of barley α-amylase on starch granules is enhanced by fusion of a starch binding domain from Aspergillus niger glucoamylase | |
| ATE513904T1 (de) | Rekombinante herstellung antimikrobieller agentien | |
| Dayler et al. | Identification of a novel bean α-amylase inhibitor with chitinolytic activity | |
| CN102083974A (zh) | 催泪蛋白的部分肽 | |
| WO2014050908A1 (ja) | ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物 | |
| JP2015525237A5 (hr) | ||
| WO2010079314A3 (en) | Polypeptides and use thereof | |
| AR039938A1 (es) | Fitasas modificadas |